Lupin Ltd

ESG rating update

• NSE Sustainability assigns Lupin ESG rating 70 for FY26, down from 71 for FY25.
• Decline due to lower Social and Governance scores by one point each.
• Lupin did not engage NSE Sustainability; rating prepared independently from public information.
• No material impact on operations or financials; rating serves informational disclosure.

Lupin Limited: Trading Window Closure from October 01, 2026 till 48 hours after the declaration of unaudited financial results for the quarter and half year ending on September 30, 2026

Regulatory milestone

• Lupin receives tentative FDA approval for Apixaban Oral Suspension 1.25 mg/mL via 505(b)(2).

Manufacturing readiness

• Final approval would enable manufacturing at Somerset, New Jersey facility for U.S. supply.

Product scope

• Oral liquid apixaban formulation for adults, including those who have difficulty swallowing tablets.

Capital / Securities

• Allotted 24,111 fully paid-up equity shares of ₹2 on vested ESOP options.
• Issued and paid-up capital now ₹91,45,79,944 comprising 45,72,89,972 shares.

Meeting Details

• Sept 17, 2026 — Kotak Healthcare Conference; in-person group meet.
• Sept 21, 2026 — J.P. Morgan India Conference; in-person group meet.

Additional Notes

• Presentations, if any, will align with Lupin’s published materials.

ESG rating update

• Crisil ESG Ratings assigned ESG 69 and Core ESG 65 for FY26, placing Lupin in 'Strong' category.
• Rating prepared independently using publicly available information; Lupin did not engage Crisil ESG Ratings.

Share Capital Update

• Allotted 30,967 fully paid-up shares under ESOP upon vested option exercise.
• Issued and paid-up capital increased to ₹91,45,31,722 with 45,72,65,861 shares.